Drugabilis

Oroxcell is an independent research organization (CRO) offering research services assessing the safety, toxicity and efficacy of active ingredients and finished formulations.

Specialized in in-vitro testing, particularly in 3D Human Models, Oroxcell is developing its business on two fronts:

• Safety & efficacy testing: From screening to GLP Compliant studies, we provide well established In-vitro platform, 2D and 3D models, for performing routine and regulatory safety testing, ADME (Absorption, Distribution, Metabolism, and Elimination) and Toxicity (sensitization, phototoxicity and genotoxicity) tests, bioanalytical studies, for evaluating pharmaceuticals, medical devices, cosmetics, nutraceuticals, home care and chemical products.

• Research & Innovation: Oroxcell provides a wide range of services including R&D project management and technical support, international consortium setup and management and regulatory & toxicology consulting.
We assist you in selecting or developing the best alternative testing methods for your safety and efficacy issues.

Oroxcell has been certified GLP compliant (Grade A, the highest grade) since 2011 by the French National Medicines and Cosmetics Safety Agency, ANSM.


Website: http://www.oroxcell.com
Contact: contact@oroxcell.com

Accepta is an innovative, industry leading chemical technology specialist serving global environmental, municipal and industrial process markets. Working closely with industry our specialist advisers combine world-class technical expertise with our own advanced treatment technologies to create practical solutions to resolve complex problems.

Accepta’s comprehensive product range is fully supported by teams of highly trained technical specialists and includes high performance chemical treatment products, analysis equipment, laboratory services, dosing pumps, meters and control equipment.

Our advanced; scientifically formulated range of speciality chemicals incorporates water treatment chemicals for steam boilers, cooling towers, cooling water systems and closed circuits; wastewater and effluent treatment chemicals, high performance industrial cleaning and janitorial chemicals, advanced polymers, state-of-the-art solid chemicals, reverse osmosis membrane products, eco-friendly biological formulations and much more.

Our high performance water quality analysis equipment is designed for chemists, microbiologists, water treatment and facilities management specialists who need to accurately test and monitor the quality of water and other aqueous solutions.

Our pumps, meters and control equipment are used extensively in a wide range of demanding commercial, industrial and process applications where reliability, accuracy, and long term performance are essential.

Across Barriers GmbH provides its customers services and consulting in the fields of in-vitro bioequivalence and pharmaceutical technological development.



Starting with analytical, physicochemical characterization, followed by testing of active com-pound properties on in vitro models for the feasibility, bioavailability, bioequivalence, and also customer oriented consultancy for drug formulation make it possible for Across Barriers to offer a complete service package for each question during the lifetime of the costumer’s product.



Across Barriers is certified in three GLP categories as well as for GMP. Since 2009 Across Barriers is FDA approved. Therefore, every project is performed under the common quality guidance but can also be conducted as a GLP or GMP study which is highly accepted at na-tional and international regulatory authorities.
A team of well-educated and experienced employees and a superbly equipped facility accom-plish the profile of Across Barriers.

We are a privately held Italian company founded in 1973. We are a fully integrated manufacturer of Cephalosporin, Carbapenem and Penicillin APIs as well as Finished Dosage Formulations (Solid and Injectable). We export our products to MORE than 100 countries all over the world.

Our production sites, most of them regularly inspected by EUROPEAN AND USA AUTHORITIES (FDA), have strict Quality Standards and our R&D Know-how make us a leading company.

Our Commitment: to work in the present while concentrating on the future, because on markets where research and technology are factors of primary importance, we have always to be on the cutting edge of progress in the development of production.

From this premise emerge Acs Dobfar's six key factors for success:
- High Quality Products
- Innovative Production Processes
- High Technology
- Market Diversification
- Customer Support
- Environment Respect

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. The small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is advancing to a clinical phase I study with a topical ophthalmic formulation, to be followed by phase II for treatment of non-infectious uveitis. Please visit www.activebiotech.com for more information.